Intravesical Injection of Botox for Treating Therapy Refractory Overactive Bladder in Females
The neurotoxin Botox (botulinum neurotoxin type A) is shown to be effective in the treatment of therapy refractory overactive bladder syndrome. Our data suggests a longer during efficacy than known from the use in striated muscle.
The aim of our study is to analyze short- and longterm efficacy after Botox treatment and to evaluate risk factors for non-responders and side effects such as urinary retention.
Overactive Bladder Syndrome
|Study Design:||Observational Model: Case-Only
Time Perspective: Retrospective
|Official Title:||Short- and Longterm Results After Intravesical Injection of Botulinum Neurotoxin Type A for Treating Therapy Refractory Overactive Bladder in Females - a Retrospective Study|
- duration of effect of Botox [ Time Frame: 1 year ] [ Designated as safety issue: No ]
|Study Start Date:||January 2010|
|Study Completion Date:||June 2010|
|Primary Completion Date:||June 2010 (Final data collection date for primary outcome measure)|
patients who received intravesical injections of botulinum neurotoxin type A
Please refer to this study by its ClinicalTrials.gov identifier: NCT01042119
|University Hospital of Zurich, Clinic for Gynaecology|
|Zurich, Switzerland, 8091|
|Principal Investigator:||David A Scheiner, MD||University Hospital of Zurich, Clinic for Gynaecology|